Chronic obstructive pulmonary disease

• 1. Introduction

  ›

  Chronic obstructive pulmonary disease, known as COPD, claimed roughly 5% of all deaths worldwide in 2021, making it the fourth-biggest killer on earth that year. At that same moment, about 213 million people were living with the condition. Many of them had no idea anything was seriously wrong for years, perhaps decades.

  COPD does not arrive suddenly. It builds, breath by breath, over a lifetime of exposure to smoke, pollution, or dust. The airways narrow. The tiny air sacs in the lungs break down. The body struggles to move oxygen into the bloodstream. By the time most people seek help, the disease has already carved out ground it will never return.

  Nearly 90% of COPD deaths in people under 70 happen in low and middle income countries. That geography is not a coincidence. It follows the fuel people cook with, the factories where they work, the air they breathe in childhood, and the healthcare they can afford. The questions worth asking are not only about lungs. They are about where you live, what you burn, and what you were exposed to before you could choose.

• 2. What the Body Goes Through

  ›

  A cardinal symptom of COPD is chronic and progressive shortness of breath, and doctors describe it as often the most distressing thing a patient faces. Breathlessness fuels anxiety. It also leads people to move less, which in turn makes the disease progress faster.

  The first sign is usually a persistent cough, though fewer than 30% of people with COPD produce mucus with it. Symptoms tend to be worse in the morning. People often underreport what they are feeling, assuming a cough is just irritation rather than something structural happening inside their airways.

  As the disease advances, the lungs can become hyperinflated. When air cannot fully escape after a breath, the lungs expand beyond their normal size, making each new breath harder to start. In severe cases, people instinctively lean forward and rest their hands on their knees, a posture called the tripod position, which helps stabilize the shoulder girdle and ease the work of breathing. Others breathe through pursed lips to slow exhalation and reduce the feeling of air hunger.

  The most violent episodes are called acute exacerbations. These flare-ups last from several days to two weeks. Viral infections account for 70% of them. Bacterial infections are the second most common trigger, with Haemophilus influenzae, Pseudomonas aeruginosa, and Streptococcus pneumoniae among the pathogens identified. In the most severe cases, vigorous coughing during a flare-up can fracture a rib or cause a brief loss of consciousness.

• 3. A Disease That Compounds

  ›

  People with COPD have up to 83% higher risk of pneumonia, atrial fibrillation, and heart failure compared to people of the same age without the condition. They also carry a 78% higher risk of depression. COPD rarely travels alone.

  Metabolic syndrome affects up to 50% of people with COPD, and when the two conditions coincide, systemic inflammation worsens. The likelihood that pulmonary hypertension will complicate COPD has been reported at 39%. Among people with COPD who are listed for lung transplantation, 82% have been documented as having pulmonary hypertension.

  Cognitive impairment is common in COPD, as it is in other conditions that restrict airflow. As thinking becomes harder, so does managing daily life. People with COPD are more likely to die of respiratory or heart-related causes than those without it, and they tend to die younger. Often, the cause of death is a comorbidity rather than the lung disease itself.

  COVID-19 added a new layer of risk. People with COPD faced higher rates of hospitalization, intensive care admission, and death from COVID-19. They were also more likely to develop long COVID, with persistent respiratory symptoms, fatigue, and cognitive problems. Distinguishing a COVID-19 episode from a COPD flare-up is difficult; the presence of lost taste or smell points toward COVID-19.

• 4. Smoke, Fuel, and Exposure

  ›

  Tobacco smoke is the leading risk factor for COPD globally, accounting for up to 70% of cases in high-income countries, and between 30% and 40% in low and middle income countries. In the United States and United Kingdom, 80-95% of people with COPD are current or former smokers. About 20% of those who smoke will develop COPD, and about 50% of heavy smokers will get it.

  Women are more susceptible to the harmful effects of tobacco smoke than men. Given the same amount of smoking, women face a higher risk. Women who smoke during pregnancy also increase the likelihood that their child will later develop COPD, a finding supported by epigenetic research showing that a gene called ACSF3 is differentially methylated in smoke-exposed fetal lungs.

  Marijuana is the second most commonly smoked substance globally. One study found that the damaging effects on large airway function of a single cannabis joint were comparable to those of 2.5 to 5 tobacco cigarettes. Marijuana smokers in that research reported the onset of respiratory symptoms ten years earlier than tobacco smokers. Smoking both substances together produces a synergistic effect at high cumulative exposure, above 50 joints lifetime, that raises risk beyond what either substance causes alone.

  Between 2 and 3 billion people, most in low-income countries, cook, heat, or light their homes with solid biomass fuels such as wood, charcoal, or dry dung. Globally, 90% of rural households use such fuels. The overall risk of COPD from indoor biomass smoke has been estimated at 3.2 for women and 1.8 for men. Women tend to do the cooking, so their exposure is longer. Children are at home while their lungs are still forming, making them especially vulnerable to damage they will carry for decades.

  Air pollution contributes an estimated 50% of the total attributable risk of COPD worldwide. It is the leading known risk factor for people who have never smoked, and has no safe threshold. A striking fact: 97% of the world's major cities fail to meet the World Health Organization's safety standards for particulate matter.

• 5. Seven Causes, Not One

  ›

  In 2023, the Global Initiative for Chronic Obstructive Lung Disease, known as GOLD, overhauled how COPD is categorized. Instead of treating it as a single disease with one origin, GOLD introduced seven distinct etiotypes, groupings based on underlying cause.

  The seven are: cigarette smoking (COPD-C); biomass and pollution exposure (COPD-P); genetic factors (COPD-G); abnormal lung development (COPD-D); COPD with asthma (COPD-A); infection-driven COPD (COPD-I); and COPD of unknown cause (COPD-U). In low and middle income countries, COPD-P and COPD-I are more prevalent, tied to biomass cooking fuels and repeated childhood respiratory infections respectively.

  These categories are not just academic. Each carries different clinical features. COPD-P, from biomass and pollution, tends to damage small airways and obstruct airflow. COPD-C, from tobacco, tends to destroy the air sacs and reduce oxygen transfer into the bloodstream. Knowing which cause is at work opens different intervention possibilities, from clean-energy cooking programs to childhood vaccination campaigns against influenza, pneumococcus, and RSV.

  The only genetic subtype with a targeted treatment is alpha-1 antitrypsin deficiency, caused by a rare mutation in the SERPINA1 gene. This mutation allows an enzyme called elastase to go unchecked in white blood cells, leading to early-onset emphysema. It accounts for roughly 1-5% of cases and affects about three to four people in every 10,000. A genome-wide collaboration called the COPDGene study has now identified more than 80 genome regions associated with COPD.

• 6. Diagnosis and Measurement

  ›

  Spirometry is the standard test for confirming COPD. It measures two values: forced expiratory volume in one second (FEV1), the most air that can be pushed out in the first second of an exhale; and forced vital capacity (FVC), the total air expelled in a full breath. Normally, 75-80% of the FVC exits in that first second. A ratio of FEV1 to FVC below 70% in someone with symptoms defines COPD.

  The diagnosis is typically considered in anyone over 35 to 40 with persistent shortness of breath, a chronic cough, or frequent winter colds, combined with a history of exposure to known risk factors. The World Health Organization recommends that everyone diagnosed with COPD be screened for alpha-1 antitrypsin deficiency.

  A chest X-ray cannot establish a COPD diagnosis on its own but can show characteristic signs such as a flattened diaphragm, increased retrosternal air space, and a tracheal deformity called a saber-sheath trachea. Assessment tools like the COPD Assessment Test (CAT) score patients on a scale of 0 to 40, where higher scores indicate more severe disease.

  GOLD's 2023 guidelines classify patients into categories A, B, and E. Class E patients are those who had one or more exacerbations leading to hospitalization in the past year, or two or more moderate exacerbations. Early case finding through primary care data, followed by spirometry, is now recommended by GOLD 2024 as likely to lead to earlier diagnosis.

• 7. Living With COPD

  ›

  COPD has no cure, but the spectrum of available treatments is wide. Quitting smoking remains the single most effective intervention. Over attempts spanning five years, nearly 40% of people achieve long-term abstinence. Combining cessation medication with behavioral therapy is more than twice as likely to work compared to behavioral therapy alone.

  Inhaled bronchodilators are the primary medications. Short-acting versions work for four to six hours. Long-acting ones, used for maintenance, last twelve to twenty-four hours. Tiotropium, a long-acting muscarinic antagonist, is associated with improved lung function, reduced flare-ups, lower hospitalization rates, and reduced mortality. The drug indacaterol requires only one inhaled dose per day and is as effective as other long-acting beta-2 agonists that need twice-daily dosing.

  Pulmonary rehabilitation, which combines exercise, disease education, and counseling, has been shown after a hospital admission to significantly reduce future hospitalizations, mortality, and quality of life decline. Tai chi appears safe for people with COPD and may improve pulmonary function compared to standard treatment, though it was not found to be more effective than other structured exercise programs.

  For people with more advanced disease, oxygen therapy is recommended where blood oxygen levels fall below specific thresholds. It is prescribed for fifteen to eighteen hours per day and is associated with reduced risk of heart failure and death. Once long-term oxygen therapy is prescribed, patients are re-assessed after 60 to 90 days to determine whether it is still needed and whether it is working. The PDE4 inhibitor roflumilast, taken orally once daily, reduces inflammation and flare-ups in moderate-to-severe cases; one notable side effect is significant weight loss, which makes it inappropriate for underweight patients.